Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals, an ASX-listed company, has recently received Australian Patent Office approval for their RECCE® Anti-Infectives, with patent protection extended until 2037 in all major pharmaceutical markets globally. The granted patent covers processes for manufacturing, uses for treating infections, and methods of administration for RECCE® 327 and RECCE® 529. CEO James Graham expressed enthusiasm for this recognition, emphasizing the significance of their innovative therapies in addressing global health challenges.

Recce Pharmaceuticals, an ASX-listed company, has recently received Australian Patent Office approval for their RECCE® Anti-Infectives, with patent protection extended until 2037 in all major pharmaceutical markets globally. The granted patent covers processes for manufacturing, uses for treating infections, and methods of administration for RECCE® 327 and RECCE® 529. CEO James Graham expressed enthusiasm for this recognition, emphasizing the significance of their innovative therapies in addressing global health challenges.<br/><br/>This milestone underscores Recce's commitment to combating viral threats and delivering impactful solutions for patients worldwide. Investors are invited to engage with any questions they may have regarding this announcement. With a focus on developing synthetic anti-infectives to combat antibiotic-resistant superbugs and viral infections, Recce's pipeline includes patented broad-spectrum treatments with potential to overcome resistance mechanisms of bacteria and viruses. Their efforts have been recognized by the WHO and FDA, highlighting the importance of their groundbreaking approaches in the medical field.

Australia Patent Granted for RECCE Anti-Infectives

Summary